This suggests that, in the case of intraarticular injection, the effects of TRPV1 blockage may involve reducing levels of MSU-related inflammatory factors in the tissue, and therefore this may be a confounding factor in estimating the real significance of TRPV1 in gout pain. This evidence concerns the gene TRPV1 and gout.